Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Covid19 Clinical Trial

Official title:

A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04729595
• Other study ID #: APC400-03
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: September 1, 2021
• Est. completion date: September 21, 2022

Study information

• Verified date: December 2022
• Source: Adamis Pharmaceuticals Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.

Description:

Phase 2/3 Adaptive, Randomized, Double-blind, placebo-controlled enrolling high risk subjects with early COVID19 infection with a primary endpoint of limiting hospitalization.

As part of the initial phase 2 portion of the study, 50 COVID positive subjects with comorbidities will be enrolled. Eligible subjects positively diagnosed COVID-19 infection will be randomized 1:1 to receive either Tempol or placebo.

An interim analysis by a DSMB will examine safety and markers of systemic inflammation during a Stage 1 interim analysis. Based on the DSMB adjudication, the Phase 3 portion of the trial will begin with a second interim analysis after enrollment of 124 subjects

This protocol will seek to enroll approximately 248 subjects > 18 years of age diagnosed with COVID-19 infection. All subjects will receive standard of care. As standard of care can vary between institution over time for the treatment of COVID-19; Off label medication use, therapies, devices, and interventions used in standard of care practice for COVID-19 is allowed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 248
• Est. completion date: September 21, 2022
• Est. primary completion date: September 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects 18 years of age and above with at least one risk factor for disease progression (i.e., age= 65, hypertension, diabetes, obesity (BMI =30 as defined by CDC), cancer, immunodeficiency and in the opinion of the investigator the risk factor is not acutely life-threatening).

• Laboratory confirmed infection of SARS-CoV-2 within 5 days of Baseline/day 1.

• Subjects must meet the severity score of Moderate or greater for two of the first ten symptoms listed in the Patient Reported Outcomes (PRO) at screening.

• Ability to travel to clinic.

• Ability to understand and sign an informed consent form.

• Female subjects of child-bearing potential who are capable of conception must be:

post- menopausal (one year or greater without menses), surgically incapable of childbearing, or practicing two effective methods of birth control. Acceptable methods include abstinence, intrauterine device, spermicide, barrier, male partner surgical sterilization and hormonal contraception. A female subject =18 years of age and of child bearing potential must agree to practice two acceptable methods of birth control during the study period.

• Ability to swallow a capsule.

• Ability to complete an electronic diary via smartphone or web.

Exclusion Criteria:

• Need for hospitalization based on severe or critical symptoms based on CDC guidance.

• Subject in long-term care facility.

• Known hypersensitivity or contra-indication to Tempol.

• Subjects taking STRONG CYP inhibitors (e.g. fluoxetine, itraconazole, quinidine, clarithromycin).

• In the opinion of the investigator, any reason that would make the follow up of the subject impossible during the study treatment and follow up period. Any reason the subject cannot comply with study and study procedures.

• Subjects receiving any other investigational agent within 4 weeks of Baseline/Day 1.

• Use of non-FDA approved (EUA or full approval)/off label treatments for COVID-19.

• Lactating females.

• History of any known chronic liver or kidney disease.

• Subjects taking drugs with a Narrow Therapeutic Index such as Cyclosporine Digoxin Flecainide Lithium Phenytoin Sirolimus Theophylline, and Warfarin.

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Drug:
• Tempol
Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.

Other:
• Placebo
Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.

Locations

Country	Name	City	State
United States	Pinnacle Research Group	Anniston	Alabama
United States	Dayton Clinical Research	Dayton	Ohio
United States	Doral medical Research	Doral	Florida
United States	Clinical Trials Center of Middle Tennessee, LLC	Franklin	Tennessee
United States	Sarkis Clinical Trials	Gainesville	Florida
United States	Center for Respiratory and Sleep Medicine	Greenwood	Indiana
United States	United Memorial Medical Center	Houston	Texas
United States	Vilo Research Group	Houston	Texas
United States	R&H Clinical Research	Katy	Texas
United States	Barrett Clinical	La Vista	Nebraska
United States	LA Universal Research	Los Angeles	California
United States	Tandem Clinical Research GI, LLC.	Marrero	Louisiana
United States	Monroe Biomedical Research	Monroe	North Carolina
United States	Omega Research Orlando, LLC	Orlando	Florida
United States	Meridian Clinical Research	Portsmouth	Virginia
United States	Eastside Research Associates	Redmond	Washington
United States	Sunrise Research Institute	Sunrise	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Adamis Pharmaceuticals Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in the rate of sustained clinical resolution1 of symptoms of COVID-19	To evaluate the difference in the rate of sustained clinical resolution1 of symptoms of COVID-19 at Day 14 by evaluating the odds ratio of the rate of sustained clinical resolution1 of symptoms of COVID-19 between Tempol + SOC vs placebo + SOC at Day 14.	14 Days from the date Randomization/First Dosing.
Secondary	Safety of Tempol + SOC vs placebo + SOC: Occurrence of Adverse Events/All cause of mortality	To evaluate the safety of Tempol + SOC vs placebo + SOC from Baseline/Day 1 through Day 60 For: Occurrence of treatment-emergent adverse events (TEAEs).; Occurrence of TEAEs leading to withdrawal of study treatment or premature study discontinuation.; All cause of mortality (death of the patient, from any cause).	60 Days from Randomization/First Dosing.
Secondary	Efficacy of Tempol on preventing hospitalization: Odds ratio of the rate of hospitalization	To evaluate the efficacy of Tempol on preventing hospitalization at Day 14 in subjects with COVID-19 by evaluating the odds ratio of the rate of hospitalization in subjects with COVID-at Day 14 between treatment arms.	14 Days from the date Randomization/First Dosing.
Secondary	Changes in functional status: Post COVID Functional Scale (PCFS)	To evaluate the changes in functional status measured by Post COVID Functional Scale (PCFS) at Baseline/Day1 to Day7, Day 14 and Day 21 by evaluating the difference in the Post COVID Functional Scale (PCFS) measurement between Tempol + SOC vs. placebo + SOC. The scale is measured from 0 - 10, with a higher score being worse.	7,14 and 21 Days from the date Randomization/First Dosing.